Provided by Tiger Fintech (Singapore) Pte. Ltd.

Krystal Biotech Inc.

132.09
+2.071.59%
Post-market: 132.090.00000.00%19:27 EDT
Volume:354.14K
Turnover:46.39M
Market Cap:3.82B
PE:31.79
High:132.35
Open:130.86
Low:127.99
Close:130.02
Loading ...

3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth

Simply Wall St.
·
24 Dec 2024

Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Simply Wall St.
·
23 Dec 2024

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Zacks
·
20 Dec 2024

Krystal Biotech Is Maintained at Buy by Chardan Capital

Dow Jones
·
19 Dec 2024

Krystal Biotech early lung cancer data ‘promising,’ says H.C. Wainwright

TIPRANKS
·
19 Dec 2024

Krystal Biotech Says Initial Results From Kyanite-1 Trial Show 'Early Evidence' of Monotherapy Activity

MT Newswires Live
·
18 Dec 2024

BRIEF-Krystal Biotech Announces Early Evidence Of Monotherapy Activity In Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung Cancer

Reuters
·
18 Dec 2024

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung Cancer

THOMSON REUTERS
·
18 Dec 2024

Krystal Biotech Inc - Reports 27% Orr and 73% Dcr in Nsclc Trial

THOMSON REUTERS
·
18 Dec 2024

Krystal: Majority of Treatment-Related Adverse Events Been Mild to Moderate in Severity & Transient, With No Grade 4 or 5 Adverse Events Observed

THOMSON REUTERS
·
18 Dec 2024

Krystal Biotech Price Target Maintained With a $221.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Dec 2024

KRYS Stock Down on Initial Clinical Updates on KB407 & KB408

Zacks
·
14 Dec 2024

Krystal Biotech announces initial update for KB408, KB407

TipRanks
·
13 Dec 2024

Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?

Zacks
·
13 Dec 2024

Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of Aatd Patients and Increase in Lung Aat to Therapeutic Levels

THOMSON REUTERS
·
12 Dec 2024

Krystal Biotech Inc - KB408 and KB407 Safe and Well Tolerated in All Doses

THOMSON REUTERS
·
12 Dec 2024

Krystal Biotech Price Target Maintained With a $221.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Dec 2024

BRIEF-Krystal Biotech Provides Update On EMA’S Ongoing Regulatory Review

Reuters
·
10 Dec 2024

Krystal Biotech Inc: Chmp Opinion NOW Expected in 1Q 2025

THOMSON REUTERS
·
10 Dec 2024

Krystal Biotech Provides Update on Ema’s Ongoing Regulatory Review of B-Vec for Dystrophic Epidermolysis Bullosa

THOMSON REUTERS
·
10 Dec 2024